CSS
XENE icon

Cubist Systematic Strategies’s Xenon Pharmaceuticals XENE Stock Holding History

Cubist Systematic Strategies’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,105
Closed -$220K – 4155
2024
Q1 		$220K Buy
+5,105
New +$235K ﹤0.01% 3037
2023
Q2 		– Sell
-1,955
Closed -$70K – 4385
2023
Q1 		$70K Buy
1,955
+1,778
+1,005% +$65.7K ﹤0.01% 3508
2022
Q4 		$6.98K Sell
177
-20,034
-99% -$730K ﹤0.01% 4066
2022
Q3 		$730K Sell
20,211
-32,467
-62% -$1.17M ﹤0.01% 2884
2022
Q2 		$1.6M Sell
52,678
-21,361
-29% -$646K 0.01% 2057
2022
Q1 		$2.26M Buy
74,039
+59,498
+409% +$1.78M 0.02% 1383
2021
Q4 		$454K Buy
14,541
+6,653
+84% +$199K ﹤0.01% 2519
2021
Q3 		$121K Buy
7,888
+6,047
+328% +$105K ﹤0.01% 2709
2021
Q2 		$34K Sell
1,841
-3,770
-67% -$69.5K ﹤0.01% 2820
2021
Q1 		$100K Sell
5,611
-382
-6% -$6.47K ﹤0.01% 2644
2020
Q4 		$92K Buy
5,993
+173
+3% +$2.02K ﹤0.01% 2417
2020
Q3 		$64K Sell
5,820
-9,590
-62% -$113K ﹤0.01% 2344
2020
Q2 		$193K Sell
15,410
-897
-6% -$11.4K ﹤0.01% 2050
2020
Q1 		$185K Sell
16,307
-9,208
-36% -$131K 0.01% 1763
2019
Q4 		$335K Buy
25,515
+23,871
+1,452% +$251K 0.01% 1782
2019
Q3 		$15K Sell
1,644
-2,826
-63% -$26.7K ﹤0.01% 2133
2019
Q2 		$44K Sell
4,470
-2,690
-38% -$25.7K ﹤0.01% 2337
2019
Q1 		$73K Buy
7,160
+675
+10% +$5.72K ﹤0.01% 2050
2018
Q4 		$41K Buy
+6,485
New +$57.6K ﹤0.01% 1893
2018
Q3 		– Sell
-600
Closed -$6K – 2109
2018
Q2 		$6K Sell
600
-1,600
-73% -$9.94K ﹤0.01% 1735
2018
Q1 		$11K Buy
2,200
+2,100
+2,100% +$7.76K ﹤0.01% 1772
2017
Q4 		$0 Buy
+100
New +$272 ﹤0.01% 2121
2015
Q4 		– Sell
-1,440
Closed -$12K – 1971
2015
Q3 		$12K Sell
1,440
-1,738
-55% -$17.3K ﹤0.01% 1805
2015
Q2 		$37K Buy
3,178
+1,089
+52% +$15.1K ﹤0.01% 1728
2015
Q1 		$35K Buy
+2,089
New +$38.6K ﹤0.01% 1790

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cubist Systematic Strategies's XENE Position: Q2 2024 in Review

Cubist Systematic Strategies sold out of Xenon Pharmaceuticals (XENE) in Q2 2024, closing a stake of 5,105 shares — an estimated $220K sold.

Cubist Systematic Strategies first reported a position in XENE in Q1 2015 and held it in 25 quarters. The position peaked at $2.26M in Q1 2022. 213 funds tracked by Wall St. Rank hold XENE as of Q2 2024.

  • Cubist Systematic Strategies reported no remaining Xenon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 5,105 Xenon Pharmaceuticals shares in Q2 2024, an estimated $220K.
  • Cubist Systematic Strategies first reported a position in Xenon Pharmaceuticals in Q1 2015 and held it in 25 quarters.
  • Cubist Systematic Strategies's Xenon Pharmaceuticals position peaked at $2.26M in Q1 2022.
  • 213 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2024.

Based on Cubist Systematic Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.